Comparative benefit from small tumour size and adjuvant chemotherapy: Clues for explaining breast cancer mortality decline

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Demicheli, Romano ^a   Ambrogi, Federico ^b  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; FLUOROURACIL; METHOTREXATE;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CLINICAL EFFECTIVENESS; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; POSTMENOPAUSE; PREMENOPAUSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; TREATMENT DURATION; TUMOR VOLUME; ADJUVANT CHEMOTHERAPY; BREAST NEOPLASMS; COMPARATIVE STUDY; MORTALITY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; SURVIVAL;

BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; FEMALE; FLUOROURACIL; HUMANS; METHOTREXATE; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS;

EID: 84908090225     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-702     Document Type: Article

References (31)

1. EBCTCG (Early Breast Cancer Trialists' Collaborative Group) Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 1998, 352:930-942. EBCTCG (Early Breast Cancer Trialists' Collaborative Group).
2. EBCTCG (Early Breast Cancer Trialists' Collaborative Group) Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998, 351:1451-1467. EBCTCG (Early Breast Cancer Trialists' Collaborative Group).
3. Bray F, McCarron P, Parkin DM. The changing global patterns of female breast cancer incidence and mortality. Breast Cancer Res 2004, 6:229-239. 10.1186/bcr932, 1064079, 15535852.
4. Bérubé S, Provencher L, Robert J, Jacob S, Hébert-Croteau N, Lemieux J, Duchesne T, Brisson J. Quantitative exploration of possible reasons for the recent improvement in breast cancer survival. Breast Cancer Res Treat 2007, 106:419-431. 10.1007/s10549-007-9503-1, 17268811.
5. Coleman MP, Gatta G, Verdecchia A, Estève J, Sant M, Storm H, Allemani C, Ciccolallo L, Santaquilani M, Berrino F, EUROCARE Working Group EUROCARE- 3 summary: cancer survival in Europe at the end of the 20th century. Ann Oncol 2003, 14(Suppl (5)):v128-v149. EUROCARE Working Group.
6. Jatoi I, Miller AB. Why is breast-cancer mortality declining?. Lancet Oncol 2003, 4:251-254. 10.1016/S1470-2045(03)01037-4, 12681269.
7. Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, Mandelblatt JS, Yakovlev AY, Habbema JD, Feuer EJ. Cancer Intervention and Surveillance Modeling Network (CISNET) Collaborators: Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 2005, 353:1784-1792. 10.1056/NEJMoa050518, 16251534.
8. Berry DA, Inoue L, Shen Y, Venier J, Cohen D, Bondy M, Theriault R, Munsell MF. Modeling the impact of treatment and screening on U.S. breast cancer mortality: a Bayesian approach. J Natl Cancer Inst Monogr 2006, 36:30-36.
9. Jorgensen KJ. Mammography screening. Benefits, harms and informed choice. Dan Med J 2013, 60:B4614.
10. Bonadonna G, Brusamolino E, Valagussa P, Rossi A, Brugnatelli L, Brambilla C, De Lena M, Tancini G, Bajetta E, Musumeci R, Veronesi U. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 1976, 294:405-410. 10.1056/NEJM197602192940801, 1246307.
11. Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med 1995, 332:901-906. 10.1056/NEJM199504063321401, 7877646.
12. Martinussen T, Scheike TH. Dynamic Regression Models for Survival Data, Springer 2006,
13. Scheike TH, Zhang MJ. Flexible competing risks regression modelling and goodness of fit. Lifetime Data Anal 2008, 14:464-483. 10.1007/s10985-008-9094-0, 2715961, 18752067.
14. Bonadonna G, Moliterni A, Zambetti M, Daidone MG, Pilotti S, Gianni L, Valagussa P. 30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study. BMJ 2005, 330(7485):217. 10.1136/bmj.38314.622095.8F, 546063, 15649903.
15. Demicheli R, Miceli R, Brambilla C, Ferrari L, Moliterni A, Zambetti M, Valagussa P, Bonadonna G. Comparative analysis of breast cancer recurrence risk for patients receiving adjuvant Cyclophosphamide, Methotrexate, Fluorouracil (CMF). Data supporting the occurrence of "cures" Breast Cancer Res Treat 1999, 53:209-215. 10.1023/A:1006134702484, 10369067.
16. Coradini D, Daidone MG, Boracchi P, Biganzoli E, Oriana S, Bresciani G, Pellizzaro C, Tomasic G, Di Fronzo G, Marubini E. Time-dependent relevance of steroid receptors in breast cancer. J Clin Oncol 2000, 18:2702-2709.
17. Demicheli R, Abbattista A, Miceli R, Valagussa P, Bonadonna G. Time distribution of the recurrence risk for breast cancer patients undergoing mastectomy: further support about the concept of tumor dormancy. Breast Cancer Res Treat 1996, 41:177-185. 10.1007/BF01807163, 8944336.
18. Patnick J. Saving lives through screening. Breast Screening Programme. Annual Rev 2008, Available at: http://www.cancerscreening.nhs.uk/breastscreen/publications/nhsbsp-annualreview2008.pdf.
19. Gøtzsche PC. Time to stop mammography screening?. CMAJ 2011, 183(17):1957-1958. 10.1503/cmaj.111721, 3225414, 22106102.
20. Humphrey LL, Helfand M, Chan BK, Woolf SH. Breast cancer screening: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002, 137(5 Part 1):347-360.
21. Haukka J, Byrnes G, Boniol M, Autier P. Trends in breast cancer mortality in Sweden before and after implementation of mammography screening. PLoS One. 2011, 6:e22422. 10.1371/journal.pone.0022422, 3180283, 21966354.
22. Vervoort MM, Draisma G, Fracheboud J, van de Poll-Franse LV, de Koning HJ. Trends in the usage of adjuvant systemic therapy for breast cancer in the Netherlands and its effect on mortality. Br J Cancer 2004, 91:242-247. 2409826, 15213715.
23. Kalager M, Zelen M, Langmark F, Adami HO. Effect of screening mammography on breast-cancer mortality in Norway. N Engl J Med 2010, 363:1203-1210. 10.1056/NEJMoa1000727, 20860502.
24. Narod SA. On being the right size: a reappraisal of mammography trials in Canada and Sweden. Lancet 1997, 349:1846.
25. Alexander FE, Anderson TJ, Brown HK, Forrest APM, Hepburn W, Kirkpatrik AE, McDonald C, Muir BB, Prescott RJ, Shepherd SM, Smith A, Warner J. The Edinburgh randomised trial of breast cancer screening: results after 10 years of follow-up. Br J Cancer 1994, 70:542-548. 10.1038/bjc.1994.342, 2033341, 8080744.
26. Demicheli R, Biganzoli E, Ardoino I, Boracchi P, Coradini D, Greco M, Moliterni A, Zambetti M, Valagussa P, Gukas ID, Bonadonna G. Recurrence and mortality dynamics for breast cancer patients undergoing mastectomy according to estrogen receptor status: different mortality but similar recurrence. Cancer Sci 2010, 101:826-830. 10.1111/j.1349-7006.2009.01472.x, 20132222.
27. Retsky M, Demicheli R, Hrushesky WJ, Forget P, De Kock M, Gukas I, Rogers RA, Baum M, Sukhatme V, Vaidya JS. Reduction of breast cancer relapses with perioperative non-steroidal anti-inflammatory drugs: new findings and a review. Curr Med Chem 2013, 20:416.
28. Autier P, Héry C, Haukka J, Boniol M, Byrnes G. Advanced breast cancer and breast cancer mortality in randomized controlled trials on mammography screening. J Clin Oncol 2009, 27:5919-5923. 10.1200/JCO.2009.22.7041, 19884547.
29. Autier P, Boniol M, Middleton R, Dorè JF, Hery C, Zheng T, Gavin A. Advanced breast cancer incidence following population-based mammographic screening. Ann Oncol 2011, 22:1726-1735. 10.1093/annonc/mdq633, 3144633, 21252058.
30. Shen Y, Yang Y, Inoue LY, Munsell MF, Miller AB, Berry DA. Role of detection method in predicting breast cancer survival: analysis of randomized screening trials. J Natl Cancer Inst 2005, 97:1195-1203. 10.1093/jnci/dji239, 16106024.
31. Jørgensen KJ, Zahl PH, Gøtzsche PC. Breast cancer mortality in organised mammography screening in Denmark: comparative study. BMJ 2010, 340:c1241. 10.1136/bmj.c1241, 2844939, 20332505.